HK1169563A1 - 利用拉喹莫德來治療多發性硬化症 - Google Patents

利用拉喹莫德來治療多發性硬化症

Info

Publication number
HK1169563A1
HK1169563A1 HK12110013.8A HK12110013A HK1169563A1 HK 1169563 A1 HK1169563 A1 HK 1169563A1 HK 12110013 A HK12110013 A HK 12110013A HK 1169563 A1 HK1169563 A1 HK 1169563A1
Authority
HK
Hong Kong
Prior art keywords
laquinimod
treatment
multiple sclerosis
sclerosis
Prior art date
Application number
HK12110013.8A
Other languages
English (en)
Inventor
Nora Tarcic
Dan Bar-Zohar
Dina Kofler
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of HK1169563A1 publication Critical patent/HK1169563A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK12110013.8A 2009-06-19 2012-10-11 利用拉喹莫德來治療多發性硬化症 HK1169563A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26907009P 2009-06-19 2009-06-19
PCT/US2010/001759 WO2010147665A1 (en) 2009-06-19 2010-06-18 Treatment of multiple sclerosis with laquinimod

Publications (1)

Publication Number Publication Date
HK1169563A1 true HK1169563A1 (zh) 2013-02-01

Family

ID=43354572

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12110013.8A HK1169563A1 (zh) 2009-06-19 2012-10-11 利用拉喹莫德來治療多發性硬化症

Country Status (26)

Country Link
US (7) US20100322900A1 (zh)
EP (2) EP2442651B1 (zh)
JP (4) JP2012530701A (zh)
KR (2) KR20120037477A (zh)
CN (2) CN107308162A (zh)
AU (2) AU2010260455A1 (zh)
BR (1) BR112012000568A2 (zh)
CY (1) CY1116727T1 (zh)
DK (1) DK2442651T3 (zh)
EA (1) EA201270041A1 (zh)
ES (1) ES2548999T3 (zh)
HK (1) HK1169563A1 (zh)
HR (1) HRP20150988T1 (zh)
HU (1) HUE026406T2 (zh)
IL (2) IL216780A0 (zh)
ME (1) ME02282B (zh)
MX (1) MX2011013902A (zh)
NZ (1) NZ597378A (zh)
PL (1) PL2442651T3 (zh)
PT (1) PT2442651E (zh)
RS (1) RS54328B1 (zh)
SG (2) SG176840A1 (zh)
SI (1) SI2442651T1 (zh)
SM (1) SMT201500262B (zh)
WO (1) WO2010147665A1 (zh)
ZA (1) ZA201200029B (zh)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2843209B2 (ja) * 1992-07-28 1999-01-06 株式会社クボタ 苗詰め装置
EP1937642B1 (en) * 2005-10-19 2014-09-10 Teva Pharmaceutical Industries Ltd Crystals of laquinimod sodium, and process for the manufacture thereof
DK2035001T3 (da) 2006-06-12 2012-02-27 Teva Pharma Stabile laquinimod-tilberedninger
ES2600920T3 (es) 2007-12-20 2017-02-13 Teva Pharmaceutical Industries, Ltd. Preparaciones estables de laquinimod
CA2736091A1 (en) * 2008-09-03 2010-03-11 Teva Pharmaceutical Industries Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
AU2010282948C1 (en) 2009-08-10 2017-03-02 Active Biotech, Ab Treatment of BDNF-related disorders using laquinimod
CN102791130B (zh) * 2010-03-03 2015-02-25 泰华制药工业有限公司 使用拉喹莫德治疗狼疮肾炎
US8501766B2 (en) * 2010-03-03 2013-08-06 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
SG183515A1 (en) * 2010-03-03 2012-10-30 Teva Pharma Treatment of lupus arthritis using laquinimod
EP2597954A4 (en) 2010-07-09 2014-01-01 Teva Pharma DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF
AU2011338647A1 (en) * 2010-12-07 2013-07-04 Teva Pharmaceutical Industries Ltd. Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
MX2014001050A (es) * 2011-07-28 2014-04-14 Teva Pharma Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero.
BR112014002092A2 (pt) * 2011-07-28 2017-02-21 Teva Pharma tratamento de esclerose múltipla com combinação de laquinimod e interferon-beta
EA201490748A1 (ru) * 2011-10-12 2014-12-30 Тева Фармасьютикал Индастриз Лтд. Лечение рассеянного склероза комбинацией лахинимода и финголимода
KR20140138694A (ko) 2012-02-03 2014-12-04 테바 파마슈티컬 인더스트리즈 리미티드 최선의 항-TNFα 요법에 실패한 크론병 환자를 치료하기 위한 라퀴니모드의 용도
AR090073A1 (es) 2012-02-16 2014-10-15 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
AR090885A1 (es) * 2012-05-02 2014-12-10 Teva Pharma Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
UY34896A (es) * 2012-07-12 2014-02-28 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
US20140107154A1 (en) * 2012-10-12 2014-04-17 Teva Pharmaceutical Industries, Ltd. Laquinimod for reducing thalamic damage in multiple sclerosis
CA2890194A1 (en) 2012-11-07 2014-05-15 Teva Pharmaceutical Industries Ltd. Amine salts of laquinimod
AU2014216199A1 (en) * 2013-02-15 2015-09-03 Teva Pharmaceutical Industries Ltd. Treatment of progressive forms of multiple sclerosis with laquinimod
BR112015021602A2 (pt) 2013-03-14 2017-07-18 Teva Pharma cristais de laquinimod de sódio e processo melhorado para a fabricação dos mesmos
WO2014152009A1 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Transdermal formulations of laquinimod
AR097792A1 (es) * 2013-09-27 2016-04-13 Teva Pharma Terapia combinada con laquinimod para el tratamiento de la esclerosis múltiple
EP3137092A4 (en) 2014-04-29 2017-10-11 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
WO2016094516A1 (en) * 2014-12-10 2016-06-16 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and a statin
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
WO2017120355A1 (en) * 2016-01-06 2017-07-13 Teva Pharmaceutical Industries Ltd. Dihydroquinolines and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696407B1 (en) * 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
EP1365794A2 (en) * 2000-07-21 2003-12-03 Lue, Tom Prevention and treatment of sexual arousal disorders
US6307050B1 (en) * 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
JP2007524626A (ja) * 2003-06-25 2007-08-30 エラン ファーマシューティカルズ，インコーポレイテッド 関節リウマチを治療する方法および組成物
US8795693B2 (en) * 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
JP2007531735A (ja) * 2004-04-01 2007-11-08 エラン ファーマシューティカルズ，インコーポレイテッド ステロイド節約剤および該節約剤を使用する方法
WO2006007837A1 (en) * 2004-07-20 2006-01-26 Tørnquist Holding Aps A lighter extension device
CA2579038A1 (en) * 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
AU2006344395B2 (en) * 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
EP1937642B1 (en) * 2005-10-19 2014-09-10 Teva Pharmaceutical Industries Ltd Crystals of laquinimod sodium, and process for the manufacture thereof
EA013907B1 (ru) * 2005-10-26 2010-08-30 Мерк Сероно С.А. Сульфонамидные производные и их применение для модулирования металлопротеаз
US20080108641A1 (en) * 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
US8367629B2 (en) * 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
CA2641513C (en) * 2006-02-28 2021-09-21 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
JP2009531304A (ja) * 2006-02-28 2009-09-03 エラン ファーマシューティカルズ，インコーポレイテッド α−４阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法
SG170058A1 (en) * 2006-03-03 2011-04-29 Elan Pharm Inc Methods of treating inflammatory and autoimmune diseases with natalizumab
EP2010214A4 (en) * 2006-04-10 2010-06-16 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
DK2035001T3 (da) * 2006-06-12 2012-02-27 Teva Pharma Stabile laquinimod-tilberedninger
WO2007146331A1 (en) * 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Tannate salt form of polypeptide mixtures, their preparation and use
ATE510538T1 (de) * 2006-08-11 2011-06-15 Univ Johns Hopkins Zusammensetzungen und verfahren für nervenschutz
CA2693697C (en) * 2007-07-11 2017-07-25 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
ES2600920T3 (es) * 2007-12-20 2017-02-13 Teva Pharmaceutical Industries, Ltd. Preparaciones estables de laquinimod
CA2736091A1 (en) * 2008-09-03 2010-03-11 Teva Pharmaceutical Industries Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
US8501766B2 (en) * 2010-03-03 2013-08-06 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
SG183515A1 (en) * 2010-03-03 2012-10-30 Teva Pharma Treatment of lupus arthritis using laquinimod
CN102791130B (zh) * 2010-03-03 2015-02-25 泰华制药工业有限公司 使用拉喹莫德治疗狼疮肾炎
WO2012006544A1 (en) * 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
EP2597954A4 (en) * 2010-07-09 2014-01-01 Teva Pharma DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF

Also Published As

Publication number Publication date
EA201270041A1 (ru) 2012-06-29
RS54328B1 (en) 2016-02-29
ZA201200029B (en) 2013-03-27
JP2012530701A (ja) 2012-12-06
US20170128435A1 (en) 2017-05-11
SI2442651T1 (sl) 2015-10-30
SG10201403397TA (en) 2014-10-30
IL252699A0 (en) 2017-07-31
HRP20150988T1 (hr) 2015-11-20
JP2015107981A (ja) 2015-06-11
EP2442651B1 (en) 2015-07-29
EP2442651A4 (en) 2012-10-31
EP3028572A1 (en) 2016-06-08
AU2016216586A1 (en) 2016-09-01
US20150164880A1 (en) 2015-06-18
PL2442651T3 (pl) 2015-12-31
PT2442651E (pt) 2015-10-22
ME02282B (me) 2016-02-20
HUE026406T2 (en) 2016-06-28
US20130272996A1 (en) 2013-10-17
MX2011013902A (es) 2012-02-23
US20180042916A1 (en) 2018-02-15
DK2442651T3 (en) 2015-09-21
BR112012000568A2 (pt) 2015-10-06
AU2010260455A1 (en) 2012-02-02
SG176840A1 (en) 2012-02-28
NZ597378A (en) 2014-08-29
JP2016199555A (ja) 2016-12-01
IL216780A0 (en) 2012-02-29
CN107308162A (zh) 2017-11-03
ES2548999T3 (es) 2015-10-22
US20160082001A1 (en) 2016-03-24
CN102802415A (zh) 2012-11-28
US20140105850A1 (en) 2014-04-17
CY1116727T1 (el) 2017-03-15
SMT201500262B (it) 2016-01-08
KR20120037477A (ko) 2012-04-19
WO2010147665A1 (en) 2010-12-23
KR20170109091A (ko) 2017-09-27
JP2018021045A (ja) 2018-02-08
US20100322900A1 (en) 2010-12-23
EP2442651A1 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
IL252699A0 (en) Use of lequinimod to treat multiple sclerosis
ZA201304280B (en) Treatment of jak2-mediated conditions
PL2467372T3 (pl) Leczenie zaburzeń związanych z BDNF z zastosowaniem lakwinimodu
ZA201301601B (en) Treatment of diseases
ZA201401217B (en) Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
EP2613786A4 (en) TREATMENT OF DISEASES
GB0919097D0 (en) Treatment of hard surfaces
GB0915515D0 (en) Treatment of vasculoproliferative conditions
EP2464227A4 (en) COMPOUNDS AND METHODS OF USE
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
IL206491A0 (en) Treatment of produce
IL256026B (en) Treatment methods
IL225896A0 (en) Treatment of mecp-2 related disorders
GB201003920D0 (en) Method of treatment
PL2460509T3 (pl) Kompozycja do leczenia brodawek
EP2585103A4 (en) METHOD OF TREATMENT
EP2440238A4 (en) Methods of Treatment
GB201013139D0 (en) An improved bed and bath
GB201008694D0 (en) An improved bed and bath
GB201002500D0 (en) Treatment of burns
HU1000688D0 (en) Use of trifluoro-phal
GB201014736D0 (en) Treatment of hepatitis C
GB201009194D0 (en) Treatment of pain
GB201005071D0 (en) Method of treatment
GB201003917D0 (en) Method of treatment

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190616